

Supporting Information

Engineering DNA templated nonribosomal peptide synthesis

Hsin-Mei Huang, Philipp Stephan and Hajo Kries*

*Correspondence to: Hajo.Kries@Leibniz-HKI.de

Table of Contents

Supporting Information	1
Experimental Procedures	3
Plasmid construction.....	3
Protein expression and purification.....	3
Preparation of template DNA for peptide synthesis	4
Peptide formation assay	4
Chemical synthesis.....	4
Analytics	4
HPLC purification of peptides	4
Method A: Solution phase peptide coupling.....	4
Method B: Removal of Boc-protecting groups	5
Synthesis of cyclo-L-ornithine (2)	5
Synthesis of Boc-D-Phe-L-Pro-OMe (5).....	5
Synthesis of Boc-D-Phe-L-Pro-OH (6).....	5
Synthesis of H ₂ N-D-Phe-L-Pro- L-cOrn HCl (8 ; fPO*).....	5
Synthesis of Boc-L-Val-L-cOrn (10).....	6
Synthesis of H ₂ N-L-Val-L-cOrn HCl (11).....	6
Synthesis of H ₂ N-D-Phe-L-Pro-L-Val-L-cOrn HCl (13 ; fPVO*)	6
Peptide quantification by UPLC-MS/MS	6
Fluorescence polarization assay.....	7
Isothermal titration calorimetry (ITC).....	7
Analytical size exclusion chromatography	8
Homology modelling	8
Sinusoidal fit of spacer length dependence	8
Supplementary Figures and Tables	9
NMR spectra	30
References	45

Experimental Procedures

Plasmid construction

Plasmids are listed in Table S1 and representative sequences are provided in GenBank file format (Table S2). DNA polymerases, T5 exonuclease, and restriction enzymes were obtained from New England Biolabs. Synthetic oligos, gene synthesis, and Sanger sequencing services were provided by Eurofins Genomics (Ebersberg, Germany).

Nonribosomal peptide synthetase (NRPS) modules were cloned from plasmids pTrc99a-*tycB1*,^[1] pSU18-*grsA*^[2] and pTrc99a-*grsB_M3574L*.^[3] Linkers between NRPS module and zinc finger domain are listed in Table S3. Zinc finger domains *zif268* (Z), *pbsII* (P), *nre* (N)^[4], and *zfb* (B) were synthesized or cloned from synthetic fragments followed by a C-terminal His₆ tag unless otherwise specified. The gene for the N-terminal docking domain (Dn) was cloned from *inxB* of *Xenorhabdus innexi* DSM 16336. The cognate C-terminal docking domain (Dc) was synthesized according to the peptide sequence of *inxA* (GenBank: KR871226)^[5] with a conservative mutation from Ile to Leu in order to embed an *Afl*I restriction site.

Recombinant genes were assembled into pSU18 vector (ChI^R) using the Hot Fusion cloning method.^[6] Chemically competent cells were prepared from *E. coli* HM0079,^[1] and transformed following the TSS protocol.^[7]

Protein expression and purification

Proteins were expressed using *E. coli* HM0079 as host which genomically encodes a phosphopantetheinyl transferase (Sfp) and generates the holo-form of NRPS modules. Media were supplemented with 25 µg/mL chloramphenicol. Bacterial cultures were incubated at 37 °C shaking at 230 rpm with an orbit diameter of 5.1 cm unless otherwise specified.

For protein expression, a preculture in LB broth was inoculated from a single colony of HM0079 freshly transformed with the relevant plasmid and incubated overnight (14-16 h). As growth medium, we used 2YT medium containing 16 g tryptone, 10 g yeast extract, 5 g NaCl in 1 L water adjusted to pH 7.0. A 500 mL Erlenmeyer flask containing 100 mL 2YT media was inoculated with 100 µL preculture and supplemented with sterile 10 µM ZnCl₂. The resulting culture was grown to mid-log phase (ca. 4 h, OD₆₀₀ ~ 0.5) and protein expression induced with 0.25 mM IPTG. Incubation was continued at 20 °C for 15-16 h. Bacteria were pelleted by centrifugation at 10,000 x g and 7 °C for 3 min and stored at -20 °C.

All reagents for protein purification were precooled to 4 °C. Procedures were performed below 10 °C except for nickel affinity chromatography. Bacterial pellets were thawed and thoroughly resuspended in one tenth of the original culture volume with buffer A1 (500 mM NaCl, 20 mM imidazole, 2 mM tris(2-carboxyethyl)phosphine [TCEP], 50 mM Tris-HCl, pH 7.4). For cell lysis, up to 25 mL suspension were contained in a 50 mL conical tube cooled on ice. Immediately before cell lysis, 0.02% of the original culture volume of a protease inhibitor cocktail (Cat.No. P8849, Sigma) were added. Ultrasonic lysis was performed for a total of 10 min using an ultrasonic homogenizer UP200St (Hielscher) with sonotrode S26d7 (7 mm diameter) at 40% amplitude and periodic on/off cycles of 2 and 3 s. Cellular debris was removed by centrifugation at 19,000 x g for 30 min. To capture His-tagged protein, the supernatant was applied to 1 mL Rotigrose-His/Ni IDA-agarose beads suspension (Cat.No. 1308.1, Carl Roth) pre-equilibrated with buffer A1 in an Econo-Column (1.5 x 15 cm; Bio-Rad). The suspension was incubated for 12.5 min for resin to settle before draining the lysate. The beads were then washed three times with 6 mL buffer A1 followed by elution with 200 µL buffer B1 (500 mM NaCl, 300 mM imidazole, 2 mM TCEP, 50 mM Tris-HCl, pH 7.4) which were discarded and two times 0.5 mL buffer B1 which contained the protein of interest.

For further purification and to remove contaminating genomic DNA, the protein was subjected to anion exchange chromatography unless specified otherwise. The protein was buffer exchanged using Vivaspin 500 centrifugal filters (30 kDa cut-off, Sartorius) into low salt buffer (20 mM NaCl, 20 mM Tris-HCl, pH 8.0, filtered) and then injected onto a MonoQ 5x50 GL anion exchange column (GE Healthcare) connected to an NGC Quest 10 Plus Chromatography System (Bio-Rad). Elution was performed at a flow rate of 1 mL/min at 10 °C with a linear gradient of 20 to 650 mM NaCl in 20 mM Tris buffer (pH 8.0) in a total volume of 7.85 mL. Fractions containing target protein were pooled, concentrated, and exchanged into DKP-M buffer (100 mM NaCl, 1 mM TCEP, 50 mM HEPES, pH 8.0) using Vivaspin 500 centrifugal filters.

Protein concentrations were determined spectrophotometrically using calculated extinction coefficients. Of each protein, two 2.5 µL aliquots were loaded onto a Take3 Plate (Biotek) and absorbance at 280 nm determined on an Epoch2 microplate reader (Biotek) equipped with Gen5 software (Biotek). The purified protein was adjusted to a concentration of 50 µM in DKP-M buffer, supplemented with 10% glycerol, frozen in liquid nitrogen, and stored at -20 °C until further assays were performed. Protein purity was verified by SDS-PAGE (Figure S6).

Preparation of template DNA for peptide synthesis

DNA templates for peptide production assays were prepared by annealing synthetic oligos (Eurofins Genomics; Table S4). The oligos were dissolved in H₂O and annealing reactions were performed in buffer AN (100 mM NaCl, 10 mM Tris-HCl, pH 7.4) containing 10 μM forward and reverse oligos. The solution was heated to 95 °C in a water bath for 3 min to denature secondary structure; the water bath was then switched off to allow gradual cooling over the course of 3 hours. The annealed dsDNA templates were stored at -20 °C.

Peptide formation assay

The assay buffer (100 mM NaCl, 50 mM HEPES, 1 mM of each amino acid substrate, 0.1 mM MgCl₂, 10 μM ZnCl₂, 2% glycerol, 0.5 mM TCEP, 5 mM adenosine-5'-triphosphate [ATP]) was formulated to enable zinc-finger binding while minimizing zinc toxicity on NRPS enzyme activity (Figure S1). NaCl and HEPES were supplied from 20x DKP-M buffer (2 M NaCl, 1 M HEPES, pH 8.0). ATP disodium salt (Cat. No. 34369-07-8, Sigma) was freshly dissolved in H₂O before use. The components were mixed thoroughly before adding enzymes and DNA templates. In the final reaction mixture, a pH of 7.5 ± 0.5 was determined with pH-Fix 2.0 - 9.0 test strips (Macherey-Nagel). Unless indicated otherwise, reactions were run at 37°C for 1 hour in a water bath.

Chemical synthesis

To verify the identities of the nonribosomal peptide products, cyclo-(FP) was purchased from Bachem, fPVOL from Cambridge Research Biochemicals and further synthetic standards were synthesized in-house. Cyclic ornithine (S-3-aminopiperidin-2-one) is abbreviated as cOrn or O*.

Analytics

NMR spectra were recorded in deuterated solvents (Carl Roth, Germany) on a Bruker AVANCE II 300 or Bruker AVANCE III 600 MHz spectrometer, equipped with a Bruker Cryoplatfom. The chemical shifts (δ) are reported in parts per million (ppm) relative to the solvent residual peak of DMSO-*d*₆ (¹H: 2.50 ppm, quintet; ¹³C: 39.5 ppm, heptet) or CDCl₃ (¹H: 7.24, singlet; ¹³C: 77.2, triplet). Some compounds show two sets of peaks due to conformational isomerism in which case only the major isomer was interpreted. **High resolution MS measurements** were performed on a Vanquish Horizon UHPLC system coupled with a Thermo QExactive HF-X Quadrupole-Orbitrap mass spectrometer (Thermo Scientific) equipped with a Acquity BEH C8 column (1.7 μm, 2.1 × 100 mm). Masses were detected by ESI as M+H⁺ adducts in positive mode.

All reagents used were reagent grade and used as supplied (purchased from Sigma-Aldrich, Bachem, Fluorochem or Carl Roth). Reactions were performed at ambient temperature under argon atmosphere in anhydrous solvents (Acros Organics) unless otherwise stated. **Analytical thin-layer chromatography** was performed on silica 60 F₂₅₄ plates (0.25 mm, Merck). Compounds were visualized by dipping the plates in a ninhydrin/acetic acid solution followed by heating.

HPLC purification of peptides

Semi-preparative HPLC of peptide products was performed using a Phenomenex Luna C18(2) (5 μm, 250 × 10 mm) column connected to a Shimadzu Nexera LC-20AR system. Hydrochloride salts of peptides were dissolved in 5% MeCN and purified by semi-preparative HPLC using the following gradient: 0 - 5 min, 5% B; 5 - 25 min, 5% - 35% B; 25-30 min, 80% B; 30-38 min, 5% B (A: H₂O with 0.1% (v/v) TFA, B: MeCN with 0.1% (v/v) TFA) with a flow rate of 8 mL/min. Fractions were collected from 5 min to 30 min. After purification, fractions containing the desired compounds (H₂N-D-Phe-L-Pro-L-cOrn: R_t = 14.1 min, H₂N-D-Phe-L-Pro-L-Val-L-cOrn: R_t = 17.4 min) were freeze dried, samples submitted to NMR measurements and pure compounds stored at -20 °C as TFA salts.

Method A: Solution phase peptide coupling

One equivalent of the carboxylic acid was dissolved in dry dichloromethane (DCM, 0.2 M solution) and cooled to 0 °C. *N,N*-Diisopropylethylamine (3 equivalents) was added drop-wise and the reaction was allowed to warm to room temperature. The acid was pre-activated through addition of hexafluorophosphate azabenzotriazole tetramethyl uronium (HATU, 1.2 equivalents) for 5 min at room temperature. Afterwards the amine (1.1 equivalents) was added and the reaction stirred at room temperature until completion as indicated by TLC (1 to 3 h). The reaction was quenched by pouring it onto 10% citric acid. Phases were separated and the aqueous phase extracted with DCM three times. The combined organic phases were washed with saturated NaHCO₃ solution and brine (one time each) and dried over Na₂SO₄. Volatiles were removed under reduced pressure. Purification by column chromatography (silica 60, DCM/MeOH 95:5) yielded the peptide product.

Method B: Removal of Boc-protecting groups

To the Boc-protected amine was added 4 M HCl in 1,4-dioxane (0.1 M final solution of the amine) at 0 °C (ice). After stirring for 5 min on ice the solution was allowed to warm to room temperature and stirred for further 3 h. Afterwards the volatile components were removed under vacuum, the residue dissolved in H₂O and freeze dried to yield the respective amine hydrochloride salt.

Synthesis of cyclo-L-ornithine (**2**)

L-Orn (**1**, 3.0 g, 17.8 mmol) was dissolved in dry MeOH (40 mL) under argon atmosphere. Trimethylsilyl chloride (10 mL, 79.3 mmol) was added portion wise and the reaction stirred for 17 h at room temperature. Afterwards, the reaction was cooled to 0 °C (ice) and a 5 M solution of NaOMe in MeOH (27 mL, 135 mmol) added. After stirring at 0 °C for 10 min, the reaction was allowed to warm to room temperature and stirred for 2.5 h. Then, the reaction was acidified to pH 6 using concentrated HCl. The solvent was removed under reduced pressure and the residue re-dissolved in iPrOH (100 mL) and filtered. The filtrate was concentrated again under reduced pressure. Purification by column chromatography (silica 60, DCM/MeOH 7:3) yielded cyclo-L-ornithine **2** (1.74 g, 15.3 mmol, 86% yield) as a white-red foam.

¹H NMR (600 MHz, DMSO): δ = 8.43 (s, 3H), 8.04 (s, 1H), 3.69 (dd, *J* = 11.0, 6.1 Hz, 1H), 3.19 – 3.04 (m, 2H), 2.27 – 2.11 (m, 1H), 1.89 – 1.80 (m, 1H), 1.78 – 1.69 (m, 2H) ppm.

¹³C NMR (151 MHz, DMSO): δ = 167.3, 48.9, 40.8, 25.0, 20.2 ppm.

UPLC-MS: *m/z* = 114.98 [M+H]⁺

Synthesis of Boc-D-Phe-L-Pro-OMe (**5**)

Method A with Boc-D-Phe-OH (**3**, 2.0 g, 7.7 mmol) as free acid and L-Pro-OMe (**4**, 1.1 g, 8.5 mmol) as amine yielded Boc-D-Phe-L-Pro-OMe **5** (2.2 g, 5.9 mmol, 77% yield) as an orange-white foam.

¹H NMR (300 MHz, CDCl₃): δ = 7.31 – 7.13 (m, 5H), 7.02 (d, *J* = 8.7 Hz, 1H), 4.43 (dd, *J* = 15.1, 8.5 Hz, 1H), 4.18 (dd, *J* = 8.4, 3.9 Hz, 1H), 3.58 (s, 3H), 3.28 – 3.12 (m, 1H), 2.92 – 2.67 (m, 3H), 2.06 – 1.93 (m, 1H), 1.90 – 1.59 (m, 3H), 1.32 (s, 9H).

¹³C NMR (75 MHz, DMSO): δ = 172.2, 170.1, 154.9, 137.5, 129.3, 128.0, 126.3, 78.0, 58.6, 53.3, 51.6, 46.3, 37.3, 28.5, 28.1, 24.3 ppm.

UPLC-MS: *m/z* = 377.13 [M+H]⁺

Synthesis of Boc-D-Phe-L-Pro-OH (**6**)

Compound **5** (530 mg, 1.4 mmol) was dissolved in THF (25 mL) and kept on ice (0 °C). 1 M LiOH (25 mL) was added, and the reaction stirred for 5 min at 0 °C. The reaction was allowed to warm to room temperature and stirred for further 2 h. THF was removed under vacuum, and the remaining aqueous solution acidified to pH 4 using 1 M HCl. The reaction mixture was extracted with DCM (20 mL) five times, the combined organic phases were washed with brine (100 mL) once, dried over Na₂SO₄ and concentrated under vacuum. Purification by column chromatography (silica 60, DCM/MeOH 95:5) yielded Boc-D-Phe-L-Pro-OH **6** (467 mg, 1.3 mmol, 93% yield) as a yellow-white solid.

¹H NMR (300 MHz, DMSO) δ = 12.54 (s, 1H), 7.35 – 7.10 (m, 5H), 6.95 (d, *J* = 8.8 Hz, 1H), 4.44 (dd, *J* = 15.0, 8.2, 1H), 4.11 (dd, *J* = 8.3, 3.5 Hz, 1H), 3.27 – 3.13 (m, 1H), 2.92 – 2.71 (m, 3H), 2.06 – 1.88 (m, 1H), 1.88 – 1.64 (m, 3H), 1.31 (s, 9H) ppm.

¹³C NMR (75 MHz, DMSO): δ = 173.1, 169.8, 154.8, 137.5, 129.3, 128.0, 126.3, 77.9, 58.6, 53.3, 46.2, 37.5, 28.5, 28.1, 24.2 ppm.

UPLC-MS: *m/z* = 385.03 [M+Na]⁺, *m/z* = 361.09 [M-H]⁻

Synthesis of H₂N-D-Phe-L-Pro-L-cOrn HCl (**8**; fPO*)

Method A with **6** (1.1 g, 2.9 mmol) as free acid and **2** (500 mg, 3.3 mmol) as amine yielded Boc-D-Phe-L-Pro-L-cOrn **7** (1.2 g, 2.6 mmol, 90% yield) as a yellow-white foam. Method B with **7** (1.2 g, 2.6 mmol) yielded H₂N-D-Phe-L-Pro-L-cOrn hydrochloride **8** (0.9 g, 2.7 mmol, quantitative yield) as a white solid.

¹H NMR (600 MHz, DMSO): δ = 8.28 (s, 2H), 8.05 (d, *J* = 8.3 Hz, 1H), 7.57 (s, 1H), 7.37 – 7.20 (m, 5H), 4.36 (s, 1H), 4.21 (dd, *J* = 7.8, 2.8 Hz, 1H), 4.08 (ddd, *J* = 10.4, 8.1, 6.4 Hz, 1H), 3.58 – 3.46 (m, 1H), 3.14 – 3.09 (m, 2H), 3.07 (dd, *J* = 13.4, 6.1 Hz, 1H), 2.96 (dd, *J* = 13.3, 8.4 Hz, 1H), 2.68 (dd, *J* = 16.8, 7.1 Hz, 1H), 1.94 – 1.86 (m, 2H), 1.84 – 1.68 (m, 4H), 1.67 – 1.56 (m, 1H), 1.49 – 1.41 (m, 1H) ppm.

¹³C NMR (151 MHz, DMSO): δ = 170.6, 169.6, 166.4, 134.5, 129.5, 128.5, 127.4, 59.7, 51.9, 48.8, 46.6, 41.0, 36.7, 29.2, 27.6, 23.7, 21.0 ppm.

UPLC-MS: *m/z* = 359.27 [M+H]⁺

HRMS: calculated for $C_{19}H_{27}N_4O_3$ $m/z = 359.2078$ $[M+H]^+$; measured $m/z = 359.2076$ $[M+H]^+$

HPLC: $R_t = 14.1$ min

Synthesis of Boc-L-Val-L-cOrn (**10**)

Method A with Boc-L-Val-OH (**9**, 1.7 g, 7.7 mmol) as free acid and **2** (0.8 g, 7 mmol) as amine yielded Boc-L-Val-L-cOrn **10** (1.4 g, 4.6 mmol, 66% yield) as a white solid.

1H NMR (300 MHz, $CDCl_3$): $\delta = 7.28$ (d, $J = 4.3$ Hz, 1H), 6.67 (s, 1H), 5.33 (d, $J = 8.6$ Hz, 1H), 4.34 – 4.18 (m, 1H), 4.10 – 3.96 (m, 1H), 3.40 – 3.23 (m, 2H), 2.58 – 2.39 (m, 1H), 2.22 – 2.01 (m, 1H), 1.96 – 1.82 (m, 2H), 1.71 – 1.50 (m, 1H), 1.42 (s, 9H), 0.95 (d, $J = 6.8$ Hz, 3H), 0.90 (d, $J = 6.8$ Hz, 3H) ppm.

^{13}C NMR (75 MHz, $CDCl_3$): $\delta = 171.9, 171.6, 155.8, 79.5, 59.6, 50.3, 41.6, 31.3, 28.3, 27.1, 20.9, 19.2, 17.6$ ppm.

UPLC-MS: $m/z = 314.14$ $[M+H]^+$

Synthesis of H_2N -L-Val-L-cOrn HCl (**11**)

Method B with **10** (500 mg, 1.6 mmol) yielded H_2N -L-Val-L-cOrn hydrochloride **11** (400 mg, 1.6 mmol, quantitative yield).

1H NMR (300 MHz, DMSO): $\delta = 8.63$ (d, $J = 8.4$ Hz, 1H), 8.27 (d, $J = 3.5$ Hz, 3H), 7.63 (s, 1H), 4.35 – 4.10 (m, 1H), 3.64 – 3.57 (m, 1H), 3.22 – 3.00 (m, 2H), 2.17 – 2.03 (m, 1H), 2.02 – 1.91 (m, 1H), 1.87 – 1.56 (m, 3H), 0.99 (d, $J = 3.6$ Hz, 3H), 0.96 (d, $J = 3.6$ Hz, 3H) ppm.

^{13}C NMR (75 MHz, DMSO): $\delta = 169.1, 167.4, 66.4, 57.3, 48.9, 41.0, 29.8, 27.5, 20.9, 18.2, 18.0$ ppm.

UPLC-MS: $m/z = 214.03$ $[M+H]^+$

Synthesis of H_2N -D-Phe-L-Pro-L-Val-L-cOrn HCl (**13**; fPVO*)

Method A with **6** as free acid and **11** (0.8 g, 7 mmol) as amine yielded Boc-D-Phe-L-Pro-L-Val-L-cOrn **12** ($m/z = 558.38$ $[M+H]^+$). Method B with **12** (176 mg, 0.3 mmol) yielded H_2N -D-Phe-L-Pro-L-Val-L-cOrn hydrochloride **13** (67.4 mg, 0.15 mmol, 50% yield) as a white solid.

1H NMR (600 MHz, DMSO): $\delta = 8.26$ (s, 3H), 7.93 (d, $J = 9.0$ Hz, 1H), 7.87 (d, $J = 7.6$ Hz, 1H), 7.58 (s, 1H), 7.37 – 7.28 (m, 3H), 7.25 – 7.18 (m, 2H), 4.44 – 4.29 (m, 2H), 4.17 – 4.04 (m, 2H), 3.58 – 3.47 (m, 1H), 3.15 – 3.09 (m, 2H), 3.06 (dd, $J = 13.3, 6.0$ Hz, 1H), 2.95 (dd, $J = 13.3, 8.3$ Hz, 1H), 2.76 – 2.64 (m, 1H), 2.05 – 1.94 (m, 2H), 1.81 – 1.69 (m, 4H), 1.60 – 1.48 (m, 1H), 1.47 – 1.39 (m, 1H), 0.89 (d, $J = 6.8$ Hz, 3H), 0.87 (d, $J = 6.8$ Hz, 3H) ppm.

^{13}C NMR (151 MHz, DMSO): $\delta = 170.9, 170.4, 169.6, 166.3, 134.5, 129.5, 128.5, 127.4, 59.4, 57.8, 51.9, 49.0, 46.7, 40.8, 36.8, 30.6, 29.3, 27.4, 23.8, 20.9, 19.3, 18.1$ ppm.

UPLC-MS: $m/z = 458.43$ $[M+H]^+$

HRMS: calculated for $C_{24}H_{36}N_5O_4$ $[M+H]^+$ $m/z = 458.2762$ $[M+H]^+$; measured $m/z = 458.2762$ $[M+H]^+$

HPLC: $R_t = 17.4$ min

Peptide quantification by UPLC-MS/MS

For quantification of peptides, a Xevo TQ-S micro tandem mass spectrometer (Waters) was used. Samples were diluted 20-fold with 50% ethanol containing 0.1% formic acid (FA) when analyzing cyclo-(fP), fPO*, and fPVO*. A 2 μ L aliquot was injected onto a CORTECS UPLC C18 column (1.6 μ m, 2.1 x 50 mm; Waters) equipped with a VanGuard pre-column (2.1 x 5 mm; Waters) connected to an H-class UPLC system (Waters). Elution was performed at 40 °C with acetonitrile (MeCN) in H_2O containing 0.1% FA at a flow rate of 0.5 mL/min (2% MeCN at 0.00 - 0.30 min, linear gradient from 2 - 50% MeCN at 0.30 - 1.50 min, 95% MeCN at 1.51 - 1.80 min, and 2% MeCN at 1.81 - 2.80 min). Ionization was performed in an ESI Z-Spray probe operated in positive mode at a capillary voltage of 0.5 kV and a desolvation temperature of 600 °C. The cone voltage was set to 20 V and multiple reaction monitoring (MRM) was performed using argon as collision gas (Table S5).

Fluorescence polarization assay

Affinity between zinc finger domains and DNA was measured in a fluorescence polarization assay. The DNA probes (Table S4) were designed according to a previous report.^[6] In short, a fluorescein-dT base was incorporated two bases upstream of the zinc finger binding site on the reverse oligo. Synthetic oligos (Eurofins) were dissolved in buffer NE (5 mM Tris-HCl, pH 8.5) at 100 μ M concentration for long term storage. Double stranded DNA probes were generated by annealing of 10 μ M forward and reverse oligos in buffer AN (100 mM NaCl, 10 mM Tris-HCl, pH 7.4). The DNA solutions were heated to 80 °C for 4 min to resolve secondary structure followed by gradual cooling to room temperature for 30 min. The resulting 10 μ M probes were stored in the dark at -20 °C.

The fluorescence polarization assay buffer (100 mM NaCl, 50 mM HEPES, 0.1 mM MgCl₂, 9 μ M ZnCl₂, 5% glycerol, 0.5 mM TCEP, 100 μ g/mL bovine serum albumin [BSA; Roth Cat.No. 90604-29-8]) resembled the buffer for peptide formation as closely as possible. The buffer was freshly prepared, filtered through a cellulose acetate (CA) filter with a pore size of 0.22 μ m (TH Geyer), and kept at room temperature for all following dilution procedures. DNA probes were diluted to 100 nM. Proteins were first diluted to 2 μ M, centrifuged at 16,000 x g and 16 °C for 8 min to remove potential precipitates, and then subjected to 2-fold serial dilutions. In black 96-well plates (BRANDplates, Cat.No. 781668, BrandTech), 90 μ L protein dilution were added to 10 μ L of 100 nM DNA probe. After thoroughly mixing by pipetting, the sample was kept at room temperature for 10 min and measured on a Synergy H1 fluorescence microplate reader (Biotek) using a polarization filter set (485/528 nm) at 24.5 \pm 1.0 °C. The polarization output (mP; Equation 1) was plotted against protein concentration (nM) and fitted to a bimolecular binding model (Equation 2) with R version 3.4.3 (Table S6).

Equation 1:

$$\text{polarization [mP]} = \frac{\text{Intensity}_{\parallel} - \text{Intensity}_{\perp}}{\text{Intensity}_{\parallel} + \text{Intensity}_{\perp}} \times 1000$$

where the incident light is subjected to a linear polarizer and

Intensity_∥: the intensity of emitted light measured using a parallel polarizing filter

Intensity_⊥: the intensity of emitted light measured using a perpendicular polarizing filter

Equation 2:

$$F = F_0 + \frac{F_{\max} - F_0}{A_0} \times \frac{(A_0 + P_0 + K_d) - \sqrt{(A_0 + P_0 + K_d)^2 - 4A_0P_0}}{2}$$

where these parameters are measured or controlled:

F: polarization

F₀: polarization in the absence of protein

A₀: DNA probe concentration

P₀: protein concentration

and the following parameters are predicted by the model:

F_{max}: polarization at saturating protein concentration

K_d: dissociation constant

Isothermal titration calorimetry (ITC)

ITC measurements (Figure S4) were performed at 25 °C in 50 mM HEPES buffer pH 8, 150 mM NaCl and 5% (v/v) glycerol using a MicroCal PEAQ-ITC calorimeter (Malvern Instruments). A solution containing 50 μ M DnGrB3 was titrated with 1 mM of the respective Dc peptides. Peptides InxA-Dc8 (QALLKGDI), InxA-Dc8-GS (QALLKGDIGS) and InxA-Dc6-GS (QALLKGGGS) were custom synthesized on a 20-24 mg scale at >95% HPLC purity by GenScript Biotech (Netherlands) as HCl salts. ITC measurements started with an initial delay of 60 s. The first injection of 0.4 μ L was followed by 24 injections with 3 μ L each for titration with peptides InxA-Dc8 and InxA-Dc8-GS or 12 injections with 3 μ L each for titration with peptide InxA-Dc6-GS. Injections were performed in intervals of 150 s. The reference power was set to 10 μ cal/s and the stir speed to 750 rpm. For each measurement, the "high feedback" mode was selected. The thermograms were analyzed using the MicroCal PEAQ-ITC Analysis Software v1.22 assuming a one site binding model. Signals in thermograms resulting from titration of the respective peptides into buffer were subtracted point-by-point as background correction. c-Values were calculated using equation 3:

Equation 3:

$$c = nK_a[M]_T$$

where K_a is the binding constant, [M]_T the total macromolecule concentration in the cell and n the binding stoichiometry. With InxA-Dc8 and InxA-Dc8-GS, binding was detected but the c-value <1 indicated unreliable quantification of the binding constants. In both cases the apparent interaction was only qualitatively noted as weak binding. With InxA-Dc6-GS, no binding was observed.

Analytical size exclusion chromatography

To physically confirm module assembly on DNA template, 2.5 μM each of TycB1-N, GrsB2-P, and GrsB3-Z were added to 2 μM of SEC-DNA in SEC sample buffer (100 mM NaCl, 50 mM HEPES pH 8.0, 35 μM ZnCl_2 , 2% glycerol, and 0.5 mM TCEP). The solution was centrifuged at 16,000 x g and 16 °C for 6 min and equilibrated at 10 °C for 20 min. A 20 μL aliquot was injected onto a Superdex 200 Increase 3.2/300 analytical size exclusion column (GE Healthcare) connected to an NGC Quest 10 Plus Chromatography System (Bio-Rad) while bypassing the column selection valve. Elution was performed at 10 °C in 2.4 mL buffer MT (100 mM NaCl, 50 mM HEPES pH 8.0) at a flow rate of 0.075 mL/min. Absorbance at 260 and 280 nm was recorded in a 5 mm flow cell.

Molecular weight standards were prepared by dissolving components of Gel Filtration Calibration Kit (GE Healthcare) separately in buffer T (150 mM NaCl, 50 mM Tris pH 7.5) at the following concentrations: 20 mg/mL thyroglobin (T), 2 mg/mL ferritin (F), 20 mg/mL aldolase (A), and 20 mg/mL conalbumin (C). A mixture containing equal volumes of each protein was stored at -80 °C. Prior to analysis, the mixture was thawed, diluted 2.5-fold with buffer MT, and centrifuged at 16,000 x g and 16 °C for 6 min. A 20 μL aliquot was analyzed via size exclusion as described above.

Homology modelling

A homology model of a two-modular DT-NRPS was built based on the sequence of GrsB3-Z and a DNA template with two corresponding binding sites and a 20 bp spacer. The DNA was modelled as ideal B-form DNA with the script "build_DNA.mcr" in YASARA (version 19.12.14).^[9] Two models of Zif268 prepared on the Swiss-Model^[10] server were aligned with the DNA in PyMOL.^[11] After energy minimization in Yasara with default settings, a homology model of the Dn/Dc domain (Swiss-Model) was changed to the sequence from GrsB3-Z at the termini and appended to one of the ZF. Next, the homology model of GrsB3-CAT (Swiss-Model) was added. The linkers between the homology models were modelled in an arbitrary low energy conformation not based on experimental data that was not further optimized. The Dn-CAT-Dc-ZF2 was duplicated and overlaid on the ZF bound to the other binding site. Since there was a slight clash between both CAT modules, a dihedral in the Dn-CAT linker was adjusted in both modules until the clash disappeared.

Sinusoidal fit of spacer length dependence

The spacer length dependence observed with the trimodular DT-NRPS (Figure 4) was nonlinearly fit to a cosine curve in R version 3.6.3 using the following code:

```
sta <- list(a=40, b=10, c=100, d=-6)
m <- nls(y~a*cos(x*2*pi/b+d) + c, start = sta)
summary(m)
```

The optimized parameters of fit are $a = 43 \pm 6$ nM (amplitude), $b = 10.1 \pm 0.3$ bp (wavelength), $c = 90 \pm 4$ nM (y-axis offset), and $d = -6.6 \pm 0.4$ bp (x-axis offset) with a residual standard error of 35.5 nM for 70 degrees of freedom.

Supplementary Figures and Tables




Figure S1.

Optimization of Zn²⁺ and Mg²⁺ concentration. Reactions were performed with 0.5 μM GrsA and TycB1 in buffer containing 100 mM NaCl, 50 mM HEPES pH 8.0, 2 % glycerol, and the indicated metal ions. Cyclo-(fP) was quantified by LC-MS/MS after 1 h at 37°C and divided by the enzyme concentration to obtain k_{obs} .




Figure S2. Portability of the docking domain.

GrsA was added to all reactions. In addition, proteins TycB1-linker o-P (I & III), TycB1-linker Dc-P (II & IV), GrsB3 (I & II), and Dn-GrsB3 (III & IV) were supplied (Table S1 and S3). The data were collected from a single batch of protein purified through nickel affinity chromatography. Reaction conditions: 1 μ M of each protein, no DNA template or $ZnCl_2$; incubation at 37°C for 3 h. The ratio of fPO* to cyclo-(fP) determined by tandem UPLC-MS is a robust parameter to assess docking domain efficiency since the ratio is less sensitive to variations in enzyme purity than the overall yield.




Figure S3. Docking domain truncation tests.

Reactions contained GrsA, TycB1-"X"-P, and Dn-GrsB3-linker com-Z. The linker "X" is specified on the x axes. Module assembly was tested on a DNA template with 30-bp spacer. Proteins were purified by nickel affinity chromatography only and the data was collected using a single batch of protein. Reaction conditions: 1 μ M of each protein, and 0.5 μ M DNA template zp30; incubation at 37°C for 2 h (left panel) or 1 h (right panel).




Figure S4. Docking domain binding affinity.

ITC thermograms (top) and derived binding curves (bottom) for titration of module Dn-GrsB3 with different variants of the InxA-Dc fragment responsible for interaction.^[12] DP: power differential between reference and sample cell. (A) Titration with full length InxA-Dc8 (K_D : $280 \pm 40 \mu\text{M}$, ΔH : $-41 \pm 6 \text{ kJ/mol}$, c : 0.177). (B) Titration with peptide InxA-Dc8-GS containing additional C-terminal amino acids GS to mimic the linker region in ZF containing constructs (K_D : $350 \pm 80 \mu\text{M}$, ΔH : $-13 \pm 3 \text{ kJ/mol}$, c : 0.141). (C) Titration with peptide InxA-Dc6-GS truncated by two amino acids.




Figure S5. Influence of binding site orientation on peptide formation efficiency.

(A) Scheme of the ZF orientation. (B) DNA-independent formation of the control cyclo-(fP). (C) DNA-dependent formation of fPO* on templates with different ZF binding site orientations and linker lengths. Reaction conditions: 0.4 μM GrsA, 0.1 μM TycB1-P, 0.5 μM GrsB3-Z, and 0.4 μM DNA template. Data points are shown for a biological duplicate.




Figure S6. SDS PAGE of purified proteins.

Electrophoretic separation was performed on Bolt 4-12% Bis-Tris Plus Gels (Thermo Fisher). Per well, 500 ng protein were applied. M: Marker (SERVA Triple Color Protein Standard III, 5 μ l used), a: GrsA (size 128 kDa), b: TycB1-P (size 131 kDa), c: TycB1-N (size 131 kDa), d: GrsB2-P (size 139 kDa), e: GrsB3-Z (size 141 kDa), f: GrsB123 (size 358 kDa). The gel was run at 200 V for 22 min in MES SDS buffer and stained with Quick Coomassie stain (Serva).

Table S1. Plasmids and proteins used in this study.

Plasmid name	Genetic layout*	Encoded protein	Usage	Source
pSU18-grsA	pSU18 vector; Plac-grsA; Chl^R	GrsA	Source of NRPS modules; Source of pSU18 vector; GrsA expression	[3]
pTrc99a-tycB1	P _{trc} -tycB1; Amp ^R	not used	Source of NRPS genes	[1]
pTrc99a_grsB_M3574L	P _{trc} -grsB; Amp ^R	not used	Source of NRPS genes	[3]
pSU18F-tycB1-P (o)	Plac-tycB1-linker o-pbsII; N' His6 tag	TycB1-linker o-P	Verify Dn & Dc portability	This study
pSU18F-tycB1-P (Dc)	Plac-tycB1-linker Dc-pbsII; N' His6 tag	TycB1-linker Dc-P	Verify Dn & Dc portability	This study
pSU18-grsB3	Plac-grsB3	GrsB3	Verify Dn & Dc portability	This study
pSU18-Dn-grsB3	Plac-Dn-grsB3	Dn-GrsB3	Verify Dn & Dc portability	This study
pSU18-tycB1-P (com)	Plac-tycB1-linker com-pbsII	TycB1-linker com-P	Dc truncation test	This study
pSU18-tycB1-P (Dc)	Plac-tycB1-linker Dc-pbsII	TycB1-linker Dc-P	Dc truncation test	This study
pSU18-tycB1-P (DcΔ1)	Plac-tycB1-linker DcΔ1-pbsII	TycB1-linker DcΔ1-P	Dc truncation test	This study
pSU18-tycB1-P (DcΔ2)	Plac-tycB1-linker DcΔ2-pbsII	TycB1-linker DcΔ2-P (TycB1-P)	Dc truncation test; DNA spacer length test	This study
pSU18-tycB1-P (DcΔ4)	Plac-tycB1-linker DcΔ4-pbsII	TycB1-linker DcΔ4-P	Dc truncation test	This study
pSU18-tycB1-P (DcΔ5)	Plac-tycB1-linker DcΔ5-pbsII	TycB1-linker DcΔ5-P	Dc truncation test	This study
pSU18-tycB1-P (DcΔ10)	Plac-tycB1-linker DcΔ10-pbsII	TycB1-linker DcΔ10-P	Dc truncation test	This study
pSU18-tycB1-P (DcΔ19)	Plac-tycB1-linker DcΔ19-pbsII	TycB1-linker DcΔ19-P	Dc truncation test	This study
pSU18-Dn-grsB3-Z (com)	Plac-Dn-grsB3-linker com-zif268	Dn-GrsB3-linker com-Z	Dc truncation test	This study
pSU18-grsB123	Plac-grsB123	GrsB123	Positive control (fused multimodule)	This study
pSU18-tycB1-N (DcΔ2)	Plac-tycB1-linker DcΔ2-nre	TycB1-N	Multimodule assembly	This study
pSU18-Dn-grsB2-P (DcΔ2)	Plac-Dn-grsB2-linker DcΔ2-pbsII	GrsB2-P	Multimodule assembly	This study
pSU18-Dn-grsB3-Z (DcΔ2)	Plac-Dn-grsB3-linker DcΔ2-zif268	GrsB3-Z	DNA spacer length test; Multimodule assembly	This study
pSU18-Z-Dn-grsB3	Plac-zif268-Dn-grsB3	Z-GrsB3	DNA spacer length test	This study
pSU18-B-Dn-grsB4	Plac-zfb-Dn-grsB4	B-GrsB4	Multimodule assembly	This study

*For protein sequences encoded by the linkers, see Table S3. Genes of NRPS modules are highlighted in yellow, genes of linkers in green and genes of zinc fingers in cyan.

Table S2. Coding sequences of recombinant NRPS proteins used in multimodule assembly.

Sequences along with annotations are shown in GenBank file format, each starting with "LOCUS" and ending with "//". The text can be saved with ".gb" file extension using text editors and visualized by molecular biology software.

```
LOCUS      tycB1-N          3522 bp ds-DNA      linear      06-FEB-2019
DEFINITION .
FEATURES             Location/Qualifiers
     CDS             1..3522
                     /label="tycB1-N"
     misc_feature    1..3126
                     /label="NRPS module tycB1"
     misc_feature    3127..3219
                     /label="linker Dc_2"
     misc_feature    3127..3204
                     /label="docking domain Dc_2"
     misc_feature    3220..3480
                     /label="zinc finger domain nre"
ORIGIN
    1 ATGGGTGTAT TTAGCAAAGA ACAAGTTCAG GATATGTATG CGTTGACCCC GATGCAAGAG
    61 GGGATGCTGT TTCACGCCTT GCTCGACCAA GAGCACAACG CGCATCTGGT ACAGATGTCG
   121 ATTTCTGTTG AGGGCGATCT TGACGTTGGG CTATTTACGG ATAGCCTGCA TGTGCTGGTA
   181 GAGAGATACG ATGTATTCCG CACGTTGTTT CTCTATGAAA AGCTGAAGCA GCCTTTGCAA
   241 GTTGTCTTGA AGCAACGGCC TATTCGGATC GAATTTTACG GCTTGTCTGC CTGCGACGAG
   301 TCCGAGAAAC AACTTCGCTA TACGCAATAC AAAAGGGCGG ATCAGGAGCG GACGTTTCAT
   361 CTGGCAAAAG ACCCGTTGAT GCGGGTCGCC CTTTTCAAA TGTCACGCA CGACTACCAG
   421 GTCATCTGGA GCTTTCATCA CATCCTCATG GACGGCTGGT GCTTCAGCAT TATTTTTGAT
   481 GACTTGCTTG CCATCTACTT GTCCTTGCAA AACAAGACGG CACTCTCCCT GGAGCCCGTA
   541 CAGCCATACA GTCGCTTTAT CAACTGGCTG GAAAAACAAA ATAAACAGGC CGCTCTCAAC
   601 TATTGGAGCG ACTATCTGGA AGCCTATGAA CAAAAGACTA CCTTGCCGAA GAAGGAAGCT
   661 GCCTTCGCCA AAGCATTTCA ACCAACCCTA TACCGCTTTT CGCTGAACCG CACCTTGACC
   721 AAGCAGCTCG GGACCATCGC CAGTCAAAAT CAAGTGACGC TATCGACGGT GATTCAAACG
   781 ATCTGGGGAG TTCTCCTGCA AAAATACAAT GCGGCCATG ATGTGCTGTT CGGCTCTGTT
   841 GTATCCGGAC GCCCTACAGA CATCGTCGGA ATCGACAAAA TGGTTGGCTT GTTTATCAAT
   901 ACGATTCCAT TCCGGGTGCA AGCGAAAGCT GGTCAAACGT TTTCCGAGCT GTTGCAAGCT
   961 GTGCACAAAA GAACTTTGCA ATCACAGCCG TATGAGCAGC TGCCTTTGTA CGACATTCAA
  1021 ACTCAGTCCG TCTTGAAGCA GGAGCTGATT GACCACCTGC TGGTCATCGA AAATTACCCG
  1081 CTGGTAGAGG CTTTGCAGAA AAAAGCATTG AACCAGCAGA TCGGCTTCAC GATTACTGCT
  1141 GTGGAAATGT TCGAGCCGAC CAATTACGAC TTGACTGTCA TGGTGATGCC AAAAGAAGAG
  1201 CTTGCCCTCC GTTTTACTA CAATGCGGCT CTGTTTACG AACAGGTCGT GCAAAAACTG
  1261 GCGGGGCACC TCCAACAGAT CGCGGATTGC GTGGCAAAAC ATTCGGGAGT CGAGCTTTGC
  1321 CAGATTCCGT TGCTGACAGA AGCAGAAACT AGCCAGCTGT TGGCAAAGCG TACGGAAACA
  1381 GCGGCTGACT ATCCTGCCGC AACCATGCAC GAGCTGTTTT CGCGGCAGGC AGAAAAACG
  1441 CTTGAGCAAG TGGCGGTAGT CTTCGCGGAT CAGCACCTGA CGTATCGGGA GCTGGATGAA
  1501 AAATCCAATC AGCTCGCCG CTTTTTGC GC AAAAAGGCA TTGGCACGGG CAGTCTTGTC
  1561 GGCACGCTGC TGGATCGCTC GCTGGACATG ATCGTCGGAA TCCTCGGCGT CTTGAAGGCA
  1621 GCGCGCGCAT TTGTGCCGAT CGACCCGAG TTGCCTGCCG AACGAATCGC TTACATGCTG
  1681 ACGCATAGCA GAGTTCATT GGTCTGACG CAAAATCATT TCGGGGCAA AGTGACCACG
  1741 CCTACAGAAA CAATTGACAT CAACACAGCG GTGATCGGGG AAGAGAGCCG CGCCCTATC
  1801 GAATCGCTCA ATCAGCCGCA TGACTTGT TT TACATCATCT ATACGTCCG AACGACAGGG
  1861 CAACCGAAAG GCGTCATGCT GGAGCATCGC AACATGGCGA ACCTGATGCG TTTTACGTTT
  1921 GATCAGACGA ACATCGCTTT TCATGAAAAA GTGTTGCA GT ATACCAGTG CAGCTTTGAT
  1981 GTTTGCTACC AGGAAATTTT CTCCACGCTG CTATCCGGG GCCAGCTCTA CCTGATCACG
  2041 AACGAGCTGA GACGGCATGT GGAAAAGCTG TTTGCTTTCA TCCAGGAAAA GCAGATCAGC
  2101 ATTTTGTCTC TCCCGGTGTC CTTCCTGAAA TTTATTTTTA ACGAACAAGA CTACGCGCAA
  2161 AGCTTCCGCG GTTGTGTCAA ACATATCATC ACGCCGGGG AACAACTCGT CGTCACACAC
  2221 GAGTCGAAA AGTATCTGCG CCAGCATCGC GTATTTTTTG ACAATCACTA CGGCCCGTCG
  2281 GAGACGCATG TGGTGACGAC ATGCACGATG GACCCGGGAC AGGCGATACC AGAGCTGCCG
  2341 CCCATCGGAA AGCCGATCAG CAACACAGGC ATTTACATTT TGGATGAAGG GCTGCAATTG
  2401 AAGCCGGAGG GGATCGTCGG GGAGTTGTAC ATTTCCGGCG CAAACGTAGG AAGAGGGTAT
```


2461 TTGCACCAGC CGGAGCTGAC CGCGGAGAAG TTTCTCGACA ATCCGTATCA GCCAGGCGAA
2521 AGAATGTACC GAACGGGTGA TCTGGCGCGT TGGTTGCCGG ATGGCCAGCT CGAATTTTTG
2581 GGCCGAATCG ACCATCAGGT AAAAATCAGG GGCCATCGCA TCGAGCTGGG AGAGATCGAA
2641 TCGCGCCTGC TCAACCATCC CGCCATCAAG GAAGCGGTGG TTATCGACCG AGCAGACGAG
2701 ACAGGCGGCA AGTTTTGTG CGCCTATGTC GTCCTGCAA AAGCGCTCAG CGACGAAGAG
2761 ATGCGGGCAT ACTTGGCGCA AGCGTTGCCG GAGTATATGA TCCCTCCTT TTTCGTGACG
2821 CTGGAGCGGA TTCCAGTCAC GCCGAACGGA AAAACAGACA GCGGAGCTTT GCCGAAGCCG
2881 GAAGGAAGTG CCAAGACGAA AGCGGATTAC GTCGCCCGA CGACTGAGCT GGAACAAAAG
2941 CTGGTCGCGA TTTGGGAGCA AATTCTTGGC GTGTCGCCGA TCGGCATTCA GGATCATTTT
3001 TTCACGCTGG GCGGCCATTC GTTAAAAGCG ATTCAGCTCA TTTCCCGCAT CCAAAGGAA
3061 TGCCAGGCGG ATGTCCCGCT GCGCGTCCTG TTTGAGCAAC CGACGATTCA AGCGCTGGCA
3121 GCGTATGTAA CAGTACATCT TCTTAAGGAG AAACGTAAGC ATTTCCAAGC GGGTCAAGAA
3181 ACTGCACAAG CTCTGTAAA AGGTGGATCC GCGGCAGCCC CTGGTGAAAA GCCTTATGCC
3241 TGCCAGTGG AAAGCTGTGA CCGCCGTTT TCTCAGAGCC ACGATTTGAC GAAACACATC
3301 CGCATCCACA CGGGACAGAA GCCCTTCAA TGTCGTATTT GTATGCGCAA TTCAGCGAT
3361 AGCAGCAAAC TGAGCCGCCA TATCCGCACG CACACCGGG AAAAACCCCTT TGCTGTGAC
3421 ATCTGTGGTC GTAAATTTGC CCGCTGGAT AATCGTACCG CTCACACCAA AATTCACACA
3481 ACCTGCTTTT GCTCGCTTAA ACATACCAT CACCATCACT AA

//

LOCUS grsB2-P 3672 bp ds-DNA linear 06-FEB-2019

DEFINITION .

FEATURES
misc_feature 3376..3630
/label="zinc finger domain pbsII"
misc_feature 3283..3375
/label="linker Dc_2"
CDS 1..3672
/label="grsB2-P"
misc_feature 232..3282
/label="NRPS module grsB2"
misc_feature 1..231
/label="docking domain Dn"
misc_feature 3283..3360
/label="docking domain Dc_2"

ORIGIN

1 ATGAAAGATG CAGCACAAAT TGTC AATGAG GCTTTAGATC AGGGAATAAC ACTGTTCTGTG
61 GCTGAGGATC GTTTGCAATA CGAAACCCGC CTCAGCAATA TTCCGGCAGA CTTAATCAGT
121 GAATGGAAC AGCATAAACA AGAGTTGATT GATTTTCTGA ACCAGCTCGA TTCATCAGAA
181 GAGCAGGTGA GTACCCATCA ACTACAGGGT ATTCCACGTT ATGAACGGGC TGAGTACTAT
241 CCTGTATCAT CAGTTCAAAA AAGAATGTTT ATTCTTAATG AATTTGATCG TTCAGGTACG
301 GCCTATAATT TACCTGGTGT TATGTTTCTA GATGAAAAAT TGAAC TACC GACAATTGGAA
361 GCAGCGGTAA AAAAATTAGT TGAGCGACAT GAAGCGCTGC GTACTTCCTT TCATTCAATT
421 AATGGGGAAC CAGTTCAGCG GGTGCATCAA AATGTAGAAC TGCAGATTGC TTATTCAGAG
481 TCAACGGAAG ATCAGGTGGA GCGAATTATT GCGGAATTTA TGCAACCATT TGCTCTTGAA
541 GTTGCTCCGT TACTTCGTGT AGGTCTTGTT AAATTGGAGG CAGAACGTCA TCTATTTATA
601 ATGGATATGC ATCATATCAT CTCGGATGGG GTATCCATGC AGATCATGAT TCAAGAAATT
661 GCTGATTTGT ATAAAGAAAA GGAAC T TCCT ACGTTAGGCA TTCAATATAA AGACTTTACT
721 GTTTGGCATA ATCGCTTGCT TCAATCGGAT GTTATTGAAA AACAAGAAGC TTACTGGCTG
781 AACGTATTTG CAGAAGAGAT TCCAGTATTG AATCTACCGA CCGATTACCC AAGACCAACC
841 ATTCAAAGCT TTGATGGTAA AAGATTTACA TTCAGTACAG GAAAGCAGCT TATGGATGAT
901 TTATAACAAG TGGCAACAGA AACAGGAACA AACTATATA TGGTTTTACT TGCTGCGTAT
961 AATGTTTTCT TATCGAAGTA TTCCGGGCAA GATGACATCG TTGTAGGAAC ACCGATTGCT
1021 GGTGATGCTC ATGCTGATGT GGAAAATATG CTGGGGATGT TTGTA AATAC ATTAGCAATA
1081 AGAAGTCGTT TAAATAATGA GGATACTTTT AAAGATTTT TAGCAAATGT AAAACAAACG
1141 GCTTTGCATG CCTATGAAAA TCCAGATTAC CCATTTGATA CGCTTGTCGA AAAGTTGGGT
1201 ATACAGAGAG ATTTAAGTAG AAATCCATTA TTTGATACGA TGTTTGTTTT GCAAAAATACG
1261 GATAGAAAGT CTTTTGAGGT TGAACAGATA ACGATTACAC CATATGTTCC AAATAGCAGA
1321 CATTCTAAAT TTGATCTTAC ATTAGAGGTT AGCGAAGAAC AAAATGAGAT TTTATTATGC
1381 CTAGAATATT GCACTAAATT ATTTACGGAT AAAACAGTTG AAAGAATGGC TGGTCATTTT
1441 TTACAGATCT TGCATGCAAT TGTTGGGAAC CCAACGATTA TAATATCAGA AATCCGATA
1501 TTGTCTGAAG AAGAAAAACA ACATATTTTA TTCGAGTTCA ACGATACGAA AACACATAT
1561 CCACATATGC AAACAATTCA AGGATTATTT GAGGAACAGG TGGAGAAGAC GCCCGACCAT
1621 GTTGCAAGTT GATGGAAAAGA CCAAACATTA ACGTATCGGG AACTTAACGA AAGAGCGAAT
1681 CAGGTCGCAA GAGTCTTACG GCAAAAAGGA GTCCAACCCG ATAATATCGT GGGATTGCTG
1741 GTTGAGCGTT CACGTGAAAT GCTCGTGGGT ATCATGGGAA TTCTTAAAGC AGGGGGAGCT
1801 TATTTACCTC TTGATCCGGA GTACCCAGCG GATAGAATTT CGTACATGAT ACAAGATTGT
1861 GGTGTACGCA TTATGCTTAC CCAACAGCAT CTTTATCTT TAGTACATGA TGAATTTGAT
1921 TGTGTTATTT TGGATGAAGA CAGTTGTGAC AAGGGGGATT CTCCAATTT GGCTCCGGTT
1981 AACCAGGCCG GGGATTTAGC CTACATCATG TACACTTCTG GTTCTACAGG AAAGCCTAAA
2041 GGTGTTATGG TAGAACATCG AAATGTGATT CGCCTTGTTA AAAATACAAA TTATGTTTCTAG
2101 GTCCGCGAAG ACGATCGTAT AATACAGACC GGAGCAATTG GATTCGATGC ACTGACATTT
2161 GAAGTTTTTTG GCTCATTGCT GCATGGAGCT GAATGTGATC CTGTTACTAA AGAGCTGCTA
2221 TTAGATGCAG AGAAACTACA CAAATTTTTA CAAGCGAATC AAATACGAT TATGTGGTTA
2281 ACTTCTCCGT TATTTAACCA ATTGTCACAA GGAACCGAAG AGATGTTTGC TGGCCTTCGC
2341 TCCCTAATTG TAGGTGGAGA TGCTTGTCT CCGAAACACA TCAATAATGT AAAGCGAAAA
2401 TGCCCTAATC TGACTATGTG GAACGGTTAC GGCCCAACAG AAAACACCAC TTTTCTTACA
2461 TGCTTTCTTA TTGATAAAGA ATATGATGAC AATATTCCGA TAGGGAAGGC CATTAGTAAT
2521 TCAACAGTGT ATATCATGGA CCGGTATGGC CAGCTTCAGC CGGTGGGTGT ACCAGGAGAA
2581 TTATGTGTAG GAGGGGATGG GGTTGCCAGG GGATATATGA ATCAGCCTGC ATTAACAGAA

2641 GAGAAGTTG TCCCAATCC ATTCGCTCCT GGTGAGAGAA TGTATCGCAC GGGGGATTTG
2701 GCAAGATGGT TGCCTGATGG AACAAATGAG TATTTAGGTC GTATTGATCA GCAGGTGAAA
2761 ATCAGGGGCT ACCGTATTGA ACCGGGAGAG ATTGAAACGC TTCTTGTGAA GCACAAAAAA
2821 GTCAAAGAAT CGGTAATCAT GGTAGTAGAG GATAATAATG GACAAAAGGC TCTATGCGCT
2881 TATTACGTTT CGGAAGAAGA AGTAACGGTA TCTGAACTGA GGAATATAT AGCTAAAGAG
2941 TTGCCTGTTT ACATGGTTCC AGCCTATTTT GTACAGATTG AACAAATGCC TCTTACACAG
3001 AACGGTAAAG TAAATCGAAG CGCGTTACCA AAACCAGATG GTGAATTTGG TACAGCAACC
3061 GAATATGTAG CGCCTAGCAG CGACATTGAA ATGAAGCTGG CAGAGATTTG GCATAATGTG
3121 TTAGGGGTAA ACAAATCGG GGTACTGGAT AACTTCTTTG AATTAGGTGG TCATTCATTA
3181 AGAGCTATGA CAATGATTTT CCAGGTACAT AAAGAGTTCG ACGTTGAATT GCCATTAATA
3241 GTGTTATTTG AAACACCAAC GATCTCTGCA TTAGCTCAAT ACGTAACAGT ACATCTTCTT
3301 AAGGAGAAAC GTAAGCATTT CCAAGCGGGT CAAGAACTG CACAAGCTCT GTTAAAAGGT
3361 GGATCCGCGG CAGCCCCTGG TGAAGGCTT TATGCCTGCC CAGAGTGCGG CAAATCTTTC
3421 TCGCAACGCG CTAACCTGCG TGCCACCAG CGCACGCATA CAGGTGAAAA ACCATATAAG
3481 TGCCCGGAGT GCGGTAAGAG CTCAGCCGC AGTGACCACT TAACTACACA CCAACGCACG
3541 CACACGGGCG AGAAGCCGTA CAAATGCCCA GAGTGCGGGA AATCTTTTAG CCGCTCAGAT
3601 GTGCTTGTTT GCCATCAACG TACACATACG ACCTGCTTTT GCTCGCTTAA ACATCACCAT
3661 CACCATCACT AA

//

LOCUS grsB3-Z 3708 bp ds-DNA linear 06-FEB-2019

DEFINITION .

FEATURES
Location/Qualifiers
CDS 1..3708
/label="grsB3-Z"
misc_feature 1..231
/label="docking domain Dn"
misc_feature 3313..3390
/label="docking domain Dc_2"
misc_feature 3313..3405
/label="linker Dc_2"
misc_feature 232..3312
/label="NRPS module grsB3"
misc_feature 3406..3666
/label="zinc finger domain zif268"

ORIGIN

```
1 ATGAAAGATG CAGCACAAAT TGTC AATGAG GCTTTAGATC AGGGAATAAC ACTGTTCTGTG
61 GCTGAGGATC GTTTGCAATA CGAAACCCGC CTCAGCAATA TTCCGGCAGA CTTAATCAGT
121 GAATGGAAC AGCATAAACA AGAGTTGATT GATTTTCTGA ACCAGCTCGA TTCATCAGAA
181 GAGCAGGTGA GTACCCATCA ACTACAGGGT ATTCACGTT ATGAACGGGC TGATTACTAT
241 CCAGTATCAT CTGCGCAAAA GAGGATGTAC ATCCTTTATG AATTTGAAGG GGCTGGCATT
301 ACCTATAATG TACCTAATGT AATGTTTATA GAAGGAAAGC TGGATTATCA GCGCTTTGAA
361 TACGCTATAA AAAGTTTGGT AAATCGACAT GAGGCGCTTC GAACGTCTTT CTATTCGCTT
421 AATGGAGAAC CAGTTCAGCG TGTACATCAA AATGTAGAGC TACAGATTGC TTATTCGGAG
481 GCGAAAGAAG ATGAGATAGA GCAAATTGTA GAAAGCTTTG TTCAACCATT TGACCTTGAA
541 ATAGCTCCGC TGCTTCGCGT AGGGCTTGTT AAATGGCAT CGGATCGCTA TTTATTCCTA
601 ATGGATATGC ATCATATTAT CTCAGATGGT GTATCAATGC AAATATAAC AAAAGAAATT
661 GCCGACTTAT ATAAAGGAAA AGAGCTTGCT GAACTGCATA TTCAGTATAA AGATTTTGCT
721 GTATGGCAAA ACGAATGGTT TCAATCTGAC GCTCTGAAA AACAGAAAAC GTATTGGTTG
781 AACACCTTTG CAGAGGATAT TCCGGTTTTA AATTTGTCAA CTGATTATCC AAGACCGACA
841 ATTCAAAGTT TTGAAGGAGA TATTGTCACG TTTAGTGCAG GGAAGCAACT TCGGAAGAA
901 TTGAAACGCC TGGCTGCAGA AACAGGGACG ACTTTGTATA TGCTTCTGTT AGCGGCGTAC
961 AATGTACTTT TACACAAATA CTCGGGACAG GAAGAAATTG TAGTAGGAAC GCCTATTGCC
1021 GGGCGATCTC ACGCAGATGT GGAAAATATT GTTGGGATGT TTGTCAATAC GCTTGCATTG
1081 AAAAATACCC CTATAGCCGT ACGCACCTTC CACGAATTCC TGTGGAAGT AAAACAAAAT
1141 GCTTTTAAAG CTTTTGAAAA TCAAGACTAT CCATTGAAA ATTTGATAGA GAAGCTGCAA
1201 GTGCGTCGCG ACTTAAGTCG CAATCCATTA TTTGATACAA TGTTTAGCCT AAGCAATATT
1261 GACGAACAAG TAGAGATAGG GATTGAGGGA TTGAACCTCA GCCCATATGA AATGCAGTAT
1321 TGGATTGCAA AATTTGATAT TTCATTCGAT ATTTTAGAAA AGCAAGATGA CATTCAATTT
1381 TATTTTAACT ATTCACGAA TCTGTTTAAA AAAGAAACGA TAGAACGATT AGCGACACAC
1441 TTTATGCATA TTTTACAGGA GATTGTTATT AATCCTGAGA TTAAGTTATG TGAATTAAT
1501 ATGCTGTCGG AAGAAGAACA GCAGCGTGTC CTGTATGACT TTAATGGCAC AGATGCAACC
1561 TACGCTACGA ATAAAATATT CCATGAGTTA TTTGAAGAAC AGGTTGAAAA AACACCAGAT
1621 CATATAGCGG TGATAGATGA AAGAGAAAAG CTTTCTATC AGGAGCTTAA TGGCAAGCG
1681 AATCAGCTGG CACGAGTGCT GCGCCAAAAA GGAGTACAGC CTAATAGCAT GGTAGGTATT
1741 ATGGTAGATC CACTACTCGA CATGATTGTA GGAATGCTTG GGGTTTTTAAA AGCAGGAGGA
1801 GCATATGTGC CTATCGATAT AGACTATCCT CAGGAACGGA TTAGCTACAT GATGGAAGAT
1861 AGTGGTGCAG CGCTCTTGTT AACACAACAA AAGTTGACAC AGCAAATTGC GTTTTCTGGT
1921 GACATTTTGT ATCTTGACCA AGAAGAATGG CTTCATGAGG AAGCTTCAA TTTAGAACCC
1981 ATCGCTCGTC CGCAGGATAT AGCCTATATC ATTTACTACT CTGGTACAAC CGGAAAGCCA
2041 AAAGGTGTGA TGATTGAGCA TCAAAGCTAT GTGAATGTAG CAATGGCATG GAAAGATGCC
2101 TATCGGTTAG ATACATTTCC GGTCCGTTTG CTTAGATGG CTAGCTTTGC CTTTGACGTA
2161 TCTGCAGGTG ATTTTGCCAG AGCACTACTT ACAGGTGGGC AATTAATTGT ATGTCCAAAT
2221 GAAGTAAAGA TGGACCCAGC TTCTTTATAT GCCATTATTA AGAAATATGA CATTACTATT
2281 TTTGAAGCAA CGCTGCTCT AGTGATTCCA TTGATGGAGT ATATTTATGA ACAGAAGCTG
2341 GATATTAGCC AGTTACAGAT TCTGATTGTC GGATCGGACA GTTGTTCGAT GGAAGACTTT
2401 AAAACCTTGG TTTCCCGTTT TGGTTCAACT ATACGTATTG TGAATAGCTA TGGAGTAACC
2461 GAAGCGTGCA TTGATTCTAG CTATTATGAA CAACCGCTTT CTTCGTTACA TGTAACAGGA
2521 ACTGTACCGA TTGGA AAAACC GTACGCTAAC ATGAAAATGT ATATTATGAA TCAATATTTG
2581 CAGATTACAG CTGTAGGTGT AATTGGAGAA TTATGTATTG GAGGAGCCGG GGTGCCCCGT
```

2641 GGATATTTAA ATAGACCGGA CTTAACAGCA GAAAAGTTG TCCCTAATCC TTTTGTCCA
2701 GGTGAAAAGC TGTATCGAAC AGGCGACTTG GCAAGATGGA TGCCGGATGG GAATGTTGAG
2761 TTTCTTGGTC GAAATGACCA TCAGGTGAAA ATCAGAGGGA TTCGAATCGA GCTTGAGAA
2821 ATCGAAGCAC AACTGCGTAA ACATGATAGC ATAAAAGAAG CAACTGTGAT CGCAAGAGAA
2881 GATCACATGA AAGAGAAATA TTTATGTGCG TATATGGTGA CCGAAGGAGA AGTAAATGTA
2941 GCTGAACTGC GTGCGTATCT AGCAAATGAT CTGCCTGCGG CAATGATTCC GTCATATTTT
3001 GTATCGCTCG AAGCAATGCC ACTTACTGCT AATGGAAAAA TTGATAAGCG ATCTTTACCA
3061 GAGCCCGATG GTTCCATATC GATAGGAACA GAATATGTAG CTCCGCGTAC CATGCTTGAG
3121 GGAAAAC TAG AAGAGATATG GAAAGATGTA TTGGGTTTAC AGCGTGTGG CATTACGAT
3181 GACTTCTTTA CAATAGGTGG CCATTCATTG AAGGCTATGG CTGTATTTT CCAAGTTCAT
3241 AAAGAATGCC AGACTGAAGT TCCTCTGCGT GTCTTATTTG AACACCTAC CATTCAAGGA
3301 CTGGCTAAAT ATGTAACAGT ACATCTTCTT AAGGAGAAAC GTAAGCATTT CCAAGCGGGT
3361 CAAGAACTG CACAAGCTCT GTTAAAAGGT GGATCCGCGG CAGCCCCTGG TGAAAAGCCT
3421 TATGCCTGCC CAGTGAAAAG CTGTGACCGC CGTTTCTCTC GTTCAGACGA ACTTACTCGT
3481 CACATCCGCA TCCACACGGG ACAGAAGCCC TTCCAATGTC GTATTTGTAT GCGCAATTT
3541 AGCCGCTCAG ACCATCTGAC TACTCATATC CGCACGCACA CCGGGGAAAA ACCCTTTGCT
3601 TGTGACATCT GTGGTCGTAA ATTTGCCCGT AGTGACGAGC GTAAGCGCCA CACCAAAT
3661 CACACAACCT GCTTTTGCTC GCTTAAACAT CACCATCACC ATCACTAA

//

LOCUS B-grsB4 4467 bp ds-DNA linear 06-FEB-2019

DEFINITION .

FEATURES
misc_feature 4..258
/label="zinc finger domain zfb"
misc_feature 502..4434
/label="NRPS module grsB4"
misc_feature 271..501
/label="docking domain Dn"
CDS 1..4467
/label="B-grsB4"

ORIGIN

1 ATGCTGGTG AAAAGCCTTA TAAATGTCCC GAATGTGGGA AGAGCTTTAG CCGTAGCGAC
61 AAACCTGGTTC GGCACCAACG CACCCATACC GGTGAAAAGC CGTATAAATG CCCGGAATGT
121 GGCAAAATCCT TTTCGACCTC TGGCGAATTA GTCCGCCATC AGCGCACTCA CACGGGTGAG
181 AAACCGTACA AATGCCAGA ATGCGGCAA TCGTTCAGTC GTCAGATGA TCTGGTGCCT
241 CATCAGCGTA CACACACCGG CCGTGGGAGC ATGAAAGATG CAGCACAAT TGTCATGAG
301 GCTTTAGATC AGGGAATAAC ACTGTTCGTG GCTGAGGATC GTTTGCAATA CGAAACCCGC
361 CTCAGCAATA TTCCGGCAGA CTTAATCAGT GAATGGAAAC AGCATAAACA AGAGTTGATT
421 GATTTTCTGA ACCAGCTCGA TTCATCAGAA GAGCAGGTGA GTACCCATCA ACTACAGGGT
481 ATTCCACGTT ATGAACGGGC TGAATATTAT CCAGTATCAT CAGCACAATA GAGAATGTTT
541 ATTGTTAATC AATTTGATGG AGTAGGAATT AGCTACAATA TGCTTCCAT CATGCTGATT
601 GAAGGAAAAC TTGAGCGAAC ACGCTTGGAA TCAGCATTTA AAAGATTGAT AGAACGACAT
661 GAGAGCCTTC GAACATCTTT TGAATAATA AATGGTAAGC CTGTACAGAA GATTCATGAG
721 GAAGTTGATT TCAATATGTC CTATCAGGTG GCTTCTAATG AACAAAGTAGA GAAGATGATC
781 GATGAGTTCA TTCAGCCTTT CGATTTAAGT GTTGACCCG TGCTTCGTGT GGAACCTTTA
841 AAATTGGAAG AAGACCGTCA TGTGCTTATA TTTGATATGC ATCATATTAT CTCAGATGGT
901 ATATCTTCCA ATATTTTGAT GAAAGAATTA GGAGAACTAT ATCAAGGTAA TGCTTTACCA
961 GAACTTCGTA TTCAATACAA GGATTTGCTT GTATGGCAA ATGAGTGGTT CCAATCAGAA
1021 GCCTTTAAAA AGCAAGAAGA ATACTGGGTA AATGTCTTCG CAGATGAACG CCCGATTCTG
1081 GATATACCGA CGGATTATCC AAGGCCGATG CAACAAAGCT TTGATGGTGC TCAACTTACA
1141 TTTGGAACCG GAAAGCAGCT TATGGATGGG TTATACAGGG TAGCAACGGA AACGGGAACA
1201 ACGCTTTATA TGGTTTTGCT TCGCGCATAT AATGTTCTTC TTTCCAAATA TTCTGGTCAA
1261 GAAGATATTA TTGTAGGGAC ACCGATTGTG GGTAGATCCC ATACTGACCT TGAGAAATAT
1321 TCGGGGATGT TTGTCAACAC GTTAGCAATG AGAAATAAAC CGGAAGGAGA AAAGACGTTT
1381 AAAGCATTTG TATCAGAAAT AAAGCAGAAAT GCACTAGCGG CTTTTGAGAA TCAGATTAT
1441 CCATTTGAAG AGCTTATCGA AAAACTAGAG ATACAAAGGG ACTTAAGCAG AAATCCATTA
1501 TTTGATACGC TCTTTAGCCT TCAAAACATA GGTGAAGAAT CATTGAACT AGCCGAATTA
1561 ACATGCAAAC CTTTCGATTT GGTAAGCAA TTAGAGCATG CCAAGTTTGA TCTGAGTCTT
1621 GTGGCAGTAG AAAAAGAGGA AGAAATTGCA TTTGGGCTTC AATACTGCAC AAAACTGTAT
1681 AAGGAAAAAA CAGTTGAACA ACTGGCTCAA CATTTTATTC AAATAGTAAA AGCAATTGTA
1741 GAAAAATCCAG ATGTCAAAT ATCTGATATT GATATGTTAT CTGAAGAAGA GAAGAAACAA
1801 ATCTTACTTG AGTTCAATGA TACGAAAATA CAATATCCGC AGAATCAAAC AATACAGGAA
1861 TTGTTTGAAG AGCAAGTGAA GAAAACACCT GAACATATAG CAATCGTATG GGAAGGGCAA
1921 GCATTAACCT ATCATGAGCT AAATATAAAA GCTAATCAGT TAGCTCGTGT ATTACGAGAA
1981 AAAGGGGTAA CCCCTAATCA TCCTGTAGCG ATTATGACGG AACGCTCATT AGAGATGATC
2041 GTAGGTATCT TTAGTATTTT GAAAGCAGGA GGAGCATATG TTCCAATTGA TCCAGCCTAT
2101 CCACAAGAAC GTATTCAATA CTTGCTTGAA GATAGCGGAG CGACGCTACT GCTTACTCAG
2161 TCACATGTAT TAAATAAATT ACCGGTCGAT ATCGAATGGT TGGATCTTAC AGATGAACAA
2221 AACTATGTAG AAGATGGTAC CAATCTTCCA TTTATGAATC AGTCAACAGA TCTTGCCTAT
2281 ATTATTTATA CATCCGGTAC AACAGGCAAG CCTAAAGGGG TTATGATTGA ACATCAAAGC
2341 ATCATCAACT GCCTGCAATG GCGGAAGGAA GAATACGAAT TTGGACCAGG GGATACGGCT
2401 CTACAAGTGT TTTCTTTTGC TTTTGTATGGA TTTGTAGCAA GTTTGTTTGC TCCGATTCTT
2461 GCAGGTGCAA CGTCTGTTCT CCCTAAGGAG GAAGAAGCAA AAGATCCAGT TGCATTGAAA
2521 AAACCTGATCG CATCAGAAGA GATTACACAT TACTACGGTG TGCTAGTTT GTTTAGTGCC
2581 ATTCTTGATG TTTCTTCTAG TAAGGATTTG CAAAATTTAC GCTGCGTCAC TTTGGGAGGA
2641 GAGAAATTAC CGGCTCAAAT TGTTAAAAAA ATCAAAGAAA AAAATAAAGA AATTGAAGTC
2701 AACAAAGAA ATGGGCCTAC TGAAAATAGT GTAGTAACTA CTATTATGCG CGATATACAG
2761 GTAGAACAAG AGATTACTAT TGGTCGCCA TTATCTAACG TAGATGTATA TATTGTCAAT
2821 TGTAATCATC AATTACAACC AGTAGGTGTA GTAGGGGAAT TATGTATTGG TGGACAGGGA

2881 CTTGCAAGAG GATATTTGAA TAAACCAGAG CTTACAGCAG ATAAATTTGT TGTAAATCCA
 2941 TTCGTACCTG GTGAACGTAT GTACAAAACC GGTGACCTTG CAAAATGGCG CTCAGATGGA
 3001 ATGATTGAAT ATGTGGGGCG TGTTGATGAA CAAGTAAAAG TAAGAGGATA TCGGATTGAG
 3061 CTTGGTGAAT TTGAATCAGC TATCCTAGAA TACGAAAAAA TTAAGGAAGC GGTAGTTATG
 3121 GTTTCGGAGC ATACTGCATC TGAACAGATG TTATGTGCTT ATATTGTAGG GGAAGAAGAT
 3181 GTACTGACTC TGGACTTAAG AAGCTATCTA GCAAAATTAC TACCAAGTTA TATGATTCCA
 3241 AACTATTTTA TCCAATTGGA TAGTATTCCG CTTACACCAA ACGGTAAAGT GGATCGTAAA
 3301 GCATTGCCTG AACCTCAAAC CATTGGCTTA ATGGCAAGGG AGTATGTTGC ACCAAGGAAT
 3361 GAAATCGAAG CACAGCTAGT ACTCATTGGG CAAGAGGTAT TAGGAATAGA ACTGATCGGT
 3421 ATTACCGATA ATTTCTTTGA ATTAGGAGGG CATTCTTTAA AGGCAACGCT TTTAGTTGCA
 3481 AAAATTTACG AGTACATGCA AATAGAGATG CCATTAAATG TTGTGTTTAA ACATFCAACT
 3541 ATTATGAAAA TAGCGGAATA TATTACACAT CAAGAATCAG AAAATAATGT ACATCAGCCT
 3601 ATTTTGGTAA ATGTAGAAGC AGATAGAGAG GCGCTATCTC TTAACGGCGA GAAGCAAAGA
 3661 AAAAATATAG AGCTACCTAT TCTGCTAAAC GAAGAAACAG ATCGAAACGT ATTCTGCTTC
 3721 GCGCCATTG GTGCACAAGG TGTTTTTTAT AAAAAGCTTG CTGAACAAAT CCCTACTGCA
 3781 TCCTTGATG GCTTTGACTT CATTGAAGAT GATGATCGAA TTCAGCAATA TATTGAATCG
 3841 ATGATTCAAA CTCAGTCAGA CGGACAATAT GTGCTAATTG GTTATTCTTC AGGAGGGAAC
 3901 CTGGCTTTTG AAGTAGCAA AGAAATGGAA AGGCAAGGAT ATAGTGATC TGATTTGGTC
 3961 TTGTTGATG TTTACTGGAA GGGAAAAGTC TTCGAGCAA CAAAAGAAGA AGAAGAAGAA
 4021 AACATAAAAA TAATAATGGA AGAATTAAGG GAAAATCCAG GAATGTTCAA TATGACACGA
 4081 GAGGATTTTG AACTGTATTT TGCGAATGAA TTTGTGAAAC AAAGTTTAC ACGGAAAATG
 4141 CGCAAATACA TGAGTTTTTA TACGCAGTTA GTTAATTATG GGGAAAGTAGA AGCTACAATT
 4201 CACCTTATAC AAGCAGAATT TGAGGAAGAA AAAATTGACG AAAACGAAAA AGCCGACGAA
 4261 GAAGAAAAAA CATATCTAGA GGAAAAATGG AATGAAAAAG CATGGAACAA AGCAGCAAAA
 4321 AGATTTGTAA AATATAACGG ATATGGCGCT CATTCTAACA TGCTAGGAGG TGATGGTTTA
 4381 GAGAGAAATT CCTCTATCCT TAAACAGATA CTACAAGGGA CATTGTAGT AAAAGGATCC
 4441 AGATCTCATC ACCATCACCA TCACTAA

//

Table S3. Linkers connecting NRPS module and zinc finger domain.

Linker	Peptide sequence	Description (underlined)
linker o	VEGGGESAYLAIPQAEGSAAA	TycB-derived, original linker following TycB1
linker com	IKDRSELTPSDFSFGRSSSTSAAA	GrsA-derived, designed in reference to pTrcHis-tycA::COM ^D ΔE ^[13]
Dn	MKDAAQIVNEALDQGITLFFVAEDRLQYETRLSNIPADLISE WKQHKQELIDFLNQLDSSEEQVSTHQLOGIPRYERA	N-terminus of InxB
linker Dc	VTVHLLKEKRKHFQAGQETAQALLKGDIGSAAA	C-terminus of InxA
linker Dc_1	VTVHLLKEKRKHFQAGQETAQALLKGDGSAAA	Truncated C-terminus of InxA
linker Dc_2	VTVHLLKEKRKHFQAGQETAQALLKGGSSAAA	Truncated C-terminus of InxA
linker Dc_4	VTVHLLKEKRKHFQAGQETAQALLGSAAA	Truncated C-terminus of InxA
linker Dc_5	VTVHLLKEKRKHFQAGQETAQALGSAAA	Truncated C-terminus of InxA
linker Dc_10	VTVHLLKEKRKHFQAGQEGSAAA	Truncated C-terminus of InxA
linker Dc_19	VTVHLLKEKGSAAA	Truncated C-terminus of InxA

Table S4. DNA templates and probes.#

Oligos	Sequence (5' to 3')
Fluorescence polarization assay	
z_F	tacaGCGTGGGCGtaat
z_R (FdT)	at [FdT] aCGCCACGCTgta
p_F	ggacGTGTGGAAAacg
p_R (FdT)	cg [FdT] tTTTCACACgtcc
n_F	ggacAAGGGTTCagatg
n_R (FdT)	ca [FdT] cTGAACCCCTTgtcc
b_F	tacaGCGGCTGGGtaat
b_R (FdT)	at [FdT] aCCCAGCCGCTgta
DNA spacer test	
zp9_F	ggtaccGCGTGGGCGGTGTGGAAAtattc
zp9_R	gaataTTTCCACACCGCCACGCggtacc
zp10_F	ggtaccGCGTGGGCGtGTGTGGAAAtattc
zp10_R	gaataTTTCCACACaCGCCACGCggtacc
zp12_F	ggtaccGCGTGGGCGtgaGTGTGGAAAtattc
zp12_R	gaataTTTCCACACtcaCGCCACGCggtacc
zp14_F	ggtaccGCGTGGGCGtgaaaGTGTGGAAAtattc
zp14_R	gaataTTTCCACACtttcaCGCCACGCggtacc
zp16_F	ggtaccGCGTGGGCGtgattaaGTGTGGAAAtattc
zp16_R	gaataTTTCCACACttaatacaCGCCACGCggtacc
zp18_F	ggtaccGCGTGGGCGtgatcataaGTGTGGAAAtattc
zp18_R	gaataTTTCCACACttatgatcaCGCCACGCggtacc
zp19_F	ggtaccGCGTGGGCGtgatccataaGTGTGGAAAtattc
zp19_R	gaataTTTCCACACttatggatcaCGCCACGCggtacc
zp20_F	ggtaccGCGTGGGCGtgatccaataaGTGTGGAAAtattc
zp20_R	gaataTTTCCACACttattggatcaCGCCACGCggtacc
zp21_F	ggtaccGCGTGGGCGtgatcctaataaGTGTGGAAAtattc
zp21_R	gaataTTTCCACACttattaggatcaCGCCACGCggtacc
zp22_F	ggtaccGCGTGGGCGtgatcctaataaGTGTGGAAAtattc
zp22_R	gaataTTTCCACACttattaaggatcaCGCCACGCggtacc
zp24_F	ggtaccGCGTGGGCGtgatcctgataataaGTGTGGAAAtattc
zp24_R	gaataTTTCCACACttattatcaggatcaCGCCACGCggtacc
zp26_F	ggtaccGCGTGGGCGtgatcctgccataataaGTGTGGAAAtattc
zp26_R	gaataTTTCCACACttattatggcaggatcaCGCCACGCggtacc
zp28_F	ggtaccGCGTGGGCGtgatcctgccataataaGTGTGGAAAtattc
zp28_R	gaataTTTCCACACttattatggggcaggatcaCGCCACGCggtacc
zp30_F	ggtaccGCGTGGGCGtgatcctgcccataataaGTGTGGAAAtattc
zp30_R	gaataTTTCCACACttattatggcgggcaggatcaCGCCACGCggtacc
zp31_F	ggtaccGCGTGGGCGtgatcctgcccagccataataaGTGTGGAAAtattc

zp31_R gaataTTTCCACACttattatggctgggcaggatcaCGCCCACGCggtacc
zp32_F ggtaccGCGTGGGCGtgatcctgcccacgccataataaGTGTGGAAAatattc
zp32_R gaataTTTCCACACttattatggcgtgggcaggatcaCGCCCACGCggtacc
zp33_F ggtaccGCGTGGGCGtgatcctgcccacgccataataaGTGTGGAAAatattc
zp33_R gaataTTTCCACACttattatggcgatgggcaggatcaCGCCCACGCggtacc
zp34_F ggtaccGCGTGGGCGtgatcctgcccacgccataataaGTGTGGAAAatattc
zp34_R gaataTTTCCACACttattatggcggatgggcaggatcaCGCCCACGCggtacc
zp36_F ggtaccGCGTGGGCGtgatcctgcccacgccataataaGTGTGGAAAatattc
zp36_R gaataTTTCCACACttattatggcggacatgggcaggatcaCGCCCACGCggtacc
zp40_F ggtaccGCGTGGGCGtgatcctgcccacgccataataaGTGTGGAAAatattc
zp40_R gaataTTTCCACACttattatggcggagacgcatgggcaggatcaCGCCCACGCggtacc
zp44_F ggtaccGCGTGGGCGtgatcctgcccacgccataataaGTGTGGAAAatattc
zp44_R gaataTTTCCACACttattatggcggagacgctgcgcatgggcaggatcaCGCCCACGCggtacc

Multimodular templating

zpn9_F gtacaGCGTGGGCGGTGTGGAAAAGGGTTCAgctgg
zpn9_R ccagcTGAACCCCTTTTCCACACCGCCACGCgttac
zpn20_F gtacaGCGTGGGCGtgatcctgcccGTGTGGAAAactcccaggacAAGGGTTCAgctgg
zpn20_R ccagcTGAACCCCTTgtcctgggagtTTTCCACACgggcaggatcaCGCCCACGCgttac
zpn32_F gtacaGCGTGGGCGtgatcctgcccacgccataatagccGTGTGGAAAacatgcccaggacAAGGGTTCAgctgg
zpn32_R ccagcTGAACCCCTTgtcctgggagacgctgcgcatggtTTTCCACACggctattatggcgggcaggatcaCGCCCACGCgttac
b'zpn_F gtacaCCCAGCCGCTGCGTGGGCGtgatcctgcccGTGTGGAAAactcccaggacAAGGGTTCAgctgg
b'zpn_R ccagcTGAACCCCTTgtcctgggagtTTTCCACACgggcaggatcaCGCCCACGCaGCGGCTGGGgttac

DNA spacer test and direction test

p'z9_F gaataCGCCCACGCGTGTGGAAAagtacc
p'z9_R ggtactTTTCCACACGCGTGGGCGtattc
p'z10_F gaataCGCCCACGCTGTGTGGAAAagtacc
p'z10_R ggtactTTTCCACACaGCGTGGGCGtattc
p'z11_F ggtactTTTCCACACgaGCGTGGGCGtattc
p'z11_R gaataCGCCCACGCTcGTGTGGAAAagtacc
p'z13_F gaataCGCCCACGCTaccGTGTGGAAAagtacc
p'z13_R ggtactTTTCCACACggtaGCGTGGGCGtattc

pz20_F ggtaccGTGTGGAAAagatccaataaGCGTGGGCGtattc
pz20_R gaataCGCCCACGCTtatttgatctTTTCCACACggtacc
pz32_F ggtaccGTGTGGAAAagatcctgcccacgccataataaGCGTGGGCGtattc
pz32_R gaataCGCCCACGCTtattatggcgtgggcaggatctTTTCCACACggtacc

SEC*

SEC-DNA_F gtacaCCCAGCCGCTGCGTGGGCGtgatcctgcccGTGTGGAAAactcccaggacAAGGGTTCAgctgg
SEC-DNA_R ccagcTGAACCCCTTgtcctgggagtTTTCCACACgggcaggatcaCGCCCACGCaGCGGCTGGGgttac

#ZF domain binding sites are shown in capital letters. The linkers in between are random sequences (lower case). [FdT]: fluorescein-dT; _F: forward oligo; _R: reverse oligo. A prime after the ZF abbreviation indicates an inverted direction of the binding site. *The SEC-DNA contains a fourth zinc finger binding site not used in this work.

Table S5. Tuning parameters for peptide quantification by tandem mass spectrometry.

Compound	Retention time (min)	Parent ion (m/z)	Daughter ion (m/z)	Collision energy (V)	Concentrations tested[#]
cyclo-(fP)	1.78	245.1	70.1	18	10 nM – 1 μ M
fPO*	1.59	359.2	212.1	18	20 pM – 200 nM
fPVO*	1.69	458.3	245.1	21	200 pM – 200 nM
fPVOL	1.73	295.2	120.1	18	172 pM – 172 nM

[#]In this concentration range, the signal was linear but the full dynamic range may be larger. Only relevant concentrations were tested.

Table S6. R script for modelling bimolecular binding.

```
# Input data are organized in three columns in a csv (comma delimited) file
# 1st column starts with title "A0", the following rows specify DNA concentrations
# 2nd column starts with title "P0", the following rows specify protein concentration
# a data point without protein is required to calculate F0
# 3rd column starts with title "F", the following rows specify fluorescence polarization

library(dplyr)
library(stringr)

# Load input data
dat1 <- read.csv(file=file.choose())
F0 = dat1[dat1$P0==0,3]
print(dat1)

# Single-ligand model, requires preassigned variable F0
lig1 <- function(P0,A0,Ka,Fmax) {
  return((P0+A0+Ka-((P0+A0+Ka)^2-4*P0*A0)^0.5)/(2*A0)*(Fmax-F0)+F0)
}
# fit to model 1
m1<-nls(F~lig1(P0, A0, Ka, Fmax),data=dat1, start = list(Ka=20,Fmax = max(dat1$F)))
summary(m1)

# plot original data in log scale
plot.new()
x_label<- "P0 (nM)"; y_label<- "F (mP)"
plot(dat1[dat1$P0!=0,]$P0, dat1[dat1$P0!=0,]$F, log="x", xlab=x_label, ylab=y_label)


# draw regression line
Pseq=seq(log10(min(dat1[dat1$P0!=0,]$P0)),log10(max(dat1[dat1$P0!=0,]$P0)),len = 100)
Pseq=10^Pseq
lines(Pseq,predict(m1,list(P0= Pseq, A0=dat1$A0[1])),col="blue",lwd=2)
abline(h=F0, lty=3)
```

Table S7. Quantification of peptides in tetramodular spacer adjustment (related to Figure 5).#


Experiment	Cyclo- (fP) (nM)	Std. dev.	fPO* (nM)	Std. dev.	fPVO* (nM)	Std. dev.	fPO*/ cyclo- [fP] (%)	Std. dev.	fPVO*/ cyclo- [fP] (%)	Std. dev.
No DNA	8860	397	25	3	20	3	0.28	0.02	0.22	0.02
9-bp spacer	8386	629	106	19	1256	228	1.25	0.13	14.92	1.60
20-bp spacer	8635	651	34	5	868	161	0.40	0.03	10.00	1.11
32-bp spacer	8887	577	23	4	512	70	0.25	0.02	5.75	0.41
GrsB123	4564	348	8	3	1336	377	0.18	0.05	29.04	6.05

#Concentrations are the average of two independent measurements.

NMR spectra




¹H NMR of compound 2 measured in DMSO-d₆




¹³C NMR of compound 2 measured in DMSO-d₆

Position	δ_c	δ_H , mult. (J in Hz)
1	48.9, CH	3.69, dd (11.0, 6.1)
2a	25.0, CH ₂	2.27 – 2.11, m
2b		1.89 – 1.80, m
3	20.2, CH ₂	1.78 – 1.69, m
4	40.8, CH ₂	3.19 – 3.04, m
5		8.04, s
6	167.3, qC	
8		8.43, broad s




¹H NMR of compound **5** measured in DMSO-d₆




¹³C NMR of compound **5** measured in DMSO-d₆

Position	δ_c ,	δ_H , mult. (J in Hz)
1	53.3, CH	4.43, dd (15.1, 8.5)
2	170.1, qC	
3		7.02, d (8.7)
4	37.3, CH ₂	2.92 – 2.67, m
5	137.5, qC	
8a	46.3, CH ₂	3.28 – 3.12, m
8b		2.92 – 2.67, m
9	24.3, CH ₂	1.90 – 1.59, m
10a	28.5, CH ₂	2.06 – 1.93, m
10b		1.90 – 1.59, m
11	58.6, CH	4.18, dd (7.7, 4.3)
12	172.2, qC	
15	128.0, CH	7.31 – 7.13, m
16	129.3, CH	7.31 – 7.13, m
17	126.3, CH	7.31 – 7.13, m
18	129.3, CH	7.31 – 7.13, m
19	128.0, CH	7.31 – 7.13, m
20	154.9, qC	
23	78.0, qC	
24	28.1, CH ₃	1.32, s
25	28.1, CH ₃	1.32, s
26	28.1, CH ₃	1.32, s
27	51.6, CH ₃	3.58, s




¹H NMR of compound 6 measured in DMSO-d₆




¹³C NMR of compound 6 measured in DMSO-d₆

Position	δ_c	δ_H , mult. (J in Hz)
1	53.3, CH	4.44, dd (15.0, 8.3)
2	169.8, qC	
3		6.95, d (8.8)
4	37.5, CH ₂	2.92 – 2.71, m
5	137.5, qC	
8a	46.2, CH ₂	3.27 – 3.13, m
8b		2.92 – 2.71, m
9	24.2, CH ₂	1.88 – 1.64, m
10a	28.5, CH ₂	2.06 – 1.88, m
10b		1.88 – 1.64, m
11	58.6, CH	4.11, dd (8.3, 3.5)
12	173.1, qC	
15	128.0, CH	7.35 – 7.10, m
16	129.3, CH	7.35 – 7.10, m
17	126.3, CH	7.35 – 7.10, m
18	129.3, CH	7.35 – 7.10, m
19	128.0, CH	7.35 – 7.10, m
20	154.8, qC	
23	77.9, qC	
24	28.1, CH ₃	1.31, s
25	28.1, CH ₃	1.31, s
26	28.1, CH ₃	1.31, s
27		12.54, broad s




¹H NMR of compound **8** measured in DMSO-d₆




¹³C NMR of compound **8** measured in DMSO-d₆

Position	δ_c	δ_H , mult. (J in Hz)
1	51.9, CH	4.36, broad s
2	170.6, qC	
3		8.28, broad s
4a	36.7, CH ₂	3.07, dd (13.4, 6.1)
4b		2.96, dd (13.3, 8.4)
5	134.5, qC	
8a	46.6, CH ₂	3.58 – 3.46, m
8b		2.68, dd (16.8, 7.1)
9a	23.7, CH ₂	1.84 – 1.68, m
9b		1.49 – 1.41, m
10	29.2, CH ₂	1.84 – 1.68, m
11	59.7, CH	4.21, dd (7.8, 2.8)
12	166.4, qC	
15	128.5, CH	7.37 – 7.20, m
16	129.5, CH	7.37 – 7.20, m
17	127.4, CH	7.37 – 7.20, m
18	129.5, CH	7.37 – 7.20, m
19	128.5, CH	7.37 – 7.20, m
30		8.05, d (8.3)
33	48.8, CH	4.08, ddd (10.4, 8.1, 6.4)
34a	27.6, CH ₂	1.94 – 1.86, m
34b		1.67 – 1.56, m
35	21.0, CH ₂	1.84 – 1.68, m
36	41.0, CH ₂	3.14 – 3.09, m
37		7.57, s
38	169.6, qC	




¹H NMR of compound 10 measured in CDCl₃




¹³C NMR of compound 10 measured in CDCl₃

Position	δ_c	δ_H , mult. (J in Hz)
1	50.3, CH	4.10 – 3.96, m
2a	27.1, CH ₂	2.22 – 2.01, m
2b		1.71 – 1.50, m
3	20.9, CH ₂	1.96 – 1.82, m
4	41.6, CH	3.40 – 3.23, m
5		6.67, s
6	171.6, qC	
8		7.28, d (4.3 Hz)
9	171.9, qC	
10	59.6, CH	4.34 – 4.18, m
12		5.33, d (8.6)
13	31.3, CH	2.58 – 2.39, m
14	17.6, CH ₃	0.90, d (6.8)
15	19.2, CH ₃	0.95, d (6.8)
16	155.8, qC	
19	79.5, qC	
20	28.3, CH ₃	1.42, s
21	28.3, CH ₃	1.42, s
22	28.3, CH ₃	1.42, s




¹H NMR of compound **11** measured in DMSO-d₆




¹³C NMR of compound **11** measured in DMSO-d₆


Position	δ_c	δ_H , mult. (J in Hz)
1	48.9, CH	3.64 – 3.57, m
2a	27.5, CH ₂	2.02 – 1.91, m
2b		1.87 – 1.56, m
3	20.9, CH ₂	1.87 – 1.56, m
4	41.0, CH ₂	3.22 – 3.00, m
5		7.63, s
6	169.1, qC	
8		8.63, d (8.4)
9	167.4, qC	
10	57.3, CH	4.35 – 4.10, m
12		8.27, d (3.5)
13	29.8, CH	2.17 – 2.03, m
14	18.2, CH ₃	0.99, d (3.6)
15	18.0, CH ₃	0.96, d (3.6)




¹H NMR of compound 13 measured in DMSO-d₆



¹³C NMR of compound 13 measured in DMSO-d₆



COSY spectra of compound **13** measured in DMSO-d₆



HSQC spectra of compound **13** measured in DMSO-d₆

Position	δ_c	δ_H , mult. (J in Hz)
1	49.0, CH	4.17 – 4.04, m
2a	27.4, CH ₂	2.05 – 1.94, m
2b		1.60 – 1.48, m
3	20.9, CH ₂	1.81 – 1.69, m
4	40.8, CH ₂	3.15 – 3.09, m
5		7.58, s
6	169.6, qC	
8		7.87, d (7.6)
9	170.4, qC	
10	57.8, CH	4.17 – 4.04, m
12		7.93, d (9.0)
13	30.6, CH	2.05 – 1.94, m
14	19.3, CH ₃	0.89, d (6.8)
15	18.1, CH ₃	0.87, d (6.8)
16	170.9, qC	
17	59.4, CH	4.44 – 4.29, m
20a	46.7, CH ₂	3.58 – 3.47, m
20b		2.76 – 2.64, m
21a	23.8, CH ₂	1.81 – 1.69, m
21b		1.47 – 1.39, m
22	29.3, CH ₂	1.81 – 1.69, m
23	166.3, qC	
25	51.9, CH	4.44 – 4.29, m
26		8.26, s
27a	36.8, CH ₂	3.06, dd (13.3, 6.0)
27b		2.95, dd (13.3, 8.3)
28	134.5, qC	
29	128.5, CH	7.25 – 7.18, m
30	129.5, CH	7.37 – 7.28, m
31	127.4, CH	7.37 – 7.28, m
32	129.5, CH	7.37 – 7.28, m
33	128.5, CH	7.25 – 7.18, m

References

- [1] S. Gruenewald, H. D. Mootz, P. Stehmeier, T. Stachelhaus, *Appl. Environ. Microbiol.* **2004**, *70*, 3282–3291.
- [2] H. Kries, R. Wachtel, A. Pabst, B. Wanner, D. Niquille, D. Hilvert, *Angew Chem Int Ed Engl* **2014**, *53*, 10105–10108.
- [3] D. L. Niquille, D. A. Hansen, T. Mori, D. Fercher, H. Kries, D. Hilvert, *Nat. Chem.* **2018**, *10*, 282–287.
- [4] H. A. Greisman, C. O. Pabo, *Science* **1997**, *275*, 657–661.
- [5] X. Cai, S. Nowak, F. Wesche, I. Bischoff, M. Kaiser, R. Fürst, H. B. Bode, *Nat. Chem.* **2017**, *9*, 379–386.
- [6] C. Fu, W. P. Donovan, O. Shikapwashya-Hasser, X. Ye, R. H. Cole, *PLoS One* **2014**, *9*, e115318.
- [7] C. T. Chung, S. L. Niemela, R. H. Miller, *Proc Natl Acad Sci U S A* **1989**, *86*, 2172–2175.
- [8] D. Jantz, J. M. Berg, *Biophys. J.* **2010**, *98*, 852–860.
- [9] E. Krieger, G. Vriend, *Bioinformatics* **2014**, *30*, 2981–2982.
- [10] M. Biasini, S. Bienert, A. Waterhouse, K. Arnold, G. Studer, T. Schmidt, F. Kiefer, T. G. Cassarino, M. Bertoni, L. Bordoli, et al., *Nucleic Acids Res.* **2014**, *42*, W252-8.
- [11] Schrodinger LLC, **2010**.
- [12] C. Hacker, X. Cai, C. Kegler, L. Zhao, A. K. Weickmann, J. P. Wurm, H. B. Bode, J. Wöhnert, *Nat. Commun.* **2018**, *9*, 4366.
- [13] M. Hahn, T. Stachelhaus, *Proc. Natl. Acad. Sci. USA* **2006**, *103*, 275–280.